ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 2802 • 2013 ACR/ARHP Annual Meeting

    A Treat-To-Target Strategy With Methotrexate and Intra-Articular Triamcinolone With Or Without Added Adalimumab Reduces Synovitis, Osteitis and Tenosynovitis and Halts Structural Damage Progression In Early Rheumatoid Arthritis: The Opera Magnetic Resonance Imaging Sub-Study

    Mette Bjørndal Axelsen1,2, Iris Eshed3, Kim Hørslev-Petersen4, Kristian Steengaard-Petersen5, Merete L. Hetland6, Jakob M. Møller7, Peter Junker8, Jan Pødenphant9, Torkell Ellingsen10, Palle Ahlquist11, Hanne M. Lindegaard12, Asta Linauskas13, Annette Schlemmer14, Mette Yde Dam15, Ib Hansen16, Hans Chr Horn17, Christian G. Ammitzbøll18, Anette Jørgensen19, Sophine B. Krintel20, Johnny Raun21, Julia S. Johansen22, Niels Steen Krogh23 and Mikkel Østergaard6, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 2Faculty of Health Sciences, Clinical Department of Orthopedics and Internal Medicine, Copenhagen University, Copenhagen, Denmark, 3Department of Radiology, Sheba Medical Center, Tel Hashomer, Israel, 4King Christian 10th Hospital for Rheumatic Diseases, South Jutland Hospital, Graasteen, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 7Department of Radiology, Copenhagen University Hospital at Herlev, Copenhagen, Denmark, 8Odense University Hospital, Odense, Denmark, 9Copenhagen University at Gentofte, Hellerup, Denmark, 10Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, 11Department of Internal Medicine, Vejle Regional Hospital, Vejle, Denmark, 12Department of Rheumatology, Odense University Hospital, Odense, Denmark, 13Vendsyssel Hospital, Hjørring, Denmark, 14Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 15Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, 16Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 17Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, 18Arhus University Hospital, Aarhus, Denmark, 19Rheumatology, Arhus University Hospital, Aarhus, Denmark, 20Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 21University of Southern Denmark, Graasten, Denmark, 22Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark, 23ZiteLab ApS, Copenhagen, Denmark

    Background/Purpose: The aim was to investigate if a treat-to-target strategy with methotrexate and intra-articular glucocorticoid suppressed synovitis and osteitis, and halted structural damage progression in…
  • Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting

    Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies

    Edward Bernton1, Antonio Polley2, Susan Zondlo2, Lynne Mitchell3 and Dennis Hourcade3, 1Protalex Inc., Summit, NJ, 2QPS Holdings LLC, Newark, DE, 3Division of Rheumatology, Washington University School of Medicine, St. Louis, MO

    Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
  • Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting

    Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study

    Takao Fujii1, Masahiro Sekiguchi2, Kiyoshi Matsui2, Masayasu Kitano2, Motomu Hashimoto3, Koichiro Ohmura4, Aihiro Yamamoto5, Hideko Nakahara6, Keiji Maeda7, Akira Yokota8, Kenji Miki9, Naoki Shimmyo10, Takanori Kuroiwa11, Kosaku Murakami12, Yoshio Ozaki13, Kenshi Higami14, Ichiro Yoshii15, Yuji Nozaki16, Takashi Ikawa17, Satoshi Morita18, Yutaka Kawahito5, Norihiro Nishimoto19, Tsuneyo Mimori4 and Hajime Sano2, 1Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, 3The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 6Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 7Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 8Yokota Clinic for Rheumatology, Osaka, Japan, 9Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, 10Kashiba Asahigaoka Hospital, Kashiba, Japan, 11Department of Rheumatology, Yukioka Hospital, Osaka, Japan, 12Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 13Kansai Medical University Hirakata Hospital, Hirakata, Japan, 14Department of Rheumatology, Higami Hospital, Nara, Japan, 15Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, 16Kinki University Faculty of Medicine, Sayama, Japan, 17Osaka Rehabilitation Hospital, Hannan, Japan, 18Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, 19Osaka Rheumatology Clinic, Osaka, Japan

    Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…
  • Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting

    Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995

    Dörte Huscher1, Katinka Albrecht2, Katja Thiele2, Sascha Bischoff2, Jutta G. Richter3, Ina Kötter4, Wolfgang Ochs5 and Angela Zink1, 1German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 4ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, 5Rheumatologist in private practice, Bayreuth, Germany

    Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…
  • Abstract Number: 1792 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis

    Daniel Dairaghi1, Penglie Zhang2, Manmohan Leleti2, Robert Berahovich3, Karen Ebsworth3, Linda Ertl3, Shichang Miao4, Zhenhua Miao3, Lisa Seitz3, Joanne Tan3, Matthew Walters3, Yu Wang3, Jay Powers5, Thomas J. Schall6 and Juan C. Jaen7, 1Biology, ChemoCentryx, Inc., Mountain View, CA, 2Chemistry, ChemoCentryx, Mountain View, CA, 3Biology, ChemoCentryx, Mountain View, CA, 4Pharmacokinetics, ChemoCentryx, Inc., Mountain View, CA, 5ChemoCentryx, Mountain View, CA, 6ChemoCentryx, Inc., Mountain View, CA, 7Discovery and Preclinical Development, ChemoCentryx, Inc., Mountain View, CA

    Background/Purpose:  Chemokines are key regulators of leukocyte activation and recruitment to sites of inflammation. Of particular relevance in rheumatoid arthritis (RA), the chemokine receptors CCR1…
  • Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting

    Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study

    Jaime Calvo-Alén1, Carmela Baamonde2, Ignacio Villa1, Víctor Martínez-Taboada3, Mario Agudo4 and Juan Gómez-Gerique5, 1Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, 2Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain

    Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
  • Abstract Number: 2381 • 2013 ACR/ARHP Annual Meeting

    The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study

    Chantal Tasset, Pille Harrison, Annegret Van der Aa, Luc Meuleners, Frédéric Vanhoutte and Gerben van 't Klooster, Galapagos NV, Mechelen, Belgium

    Background/Purpose: GLPG0634 is an oral, selective inhibitor of Janus kinase 1 (JAK1). JAKs signal for cytokines and growth factors, including those involved in rheumatoid arthritis…
  • Abstract Number: 1793 • 2013 ACR/ARHP Annual Meeting

    Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate

    Michael Weinblatt1, Mark C. Genovese2, Meilien Ho3, Sally Hollis3, Krystyna Rosiak-Jedrychowicz4, Arthur Kavanaugh5, David Millson3, Gustavo Leon6, Millie Wang3 and Désiréé van der Heijde7, 1Division of Rheumatology, Brigham & Women's Hospital, Boston, MA, 2Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, 3AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 4Przychodnia Neuromedyka, Zyrardów, Poland, 5University of California, San Diego, La Jolla, CA, 6Instituto de Ginecología y Reproducción-Cirugía Mínimamente Invasiva, Surco, Peru, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 52-wk study (NCT01197521) compared Fosta vs placebo (PBO) + methotrexate (MTX) in patients (pts) with active…
  • Abstract Number: 473 • 2013 ACR/ARHP Annual Meeting

    Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience

    Denis Choquette1, William Bensen2, Andrew Chow3, John T. Kelsall4, Maqbool K. Sheriff5, Jude F. Rodrigues6, Emmanouil Rampakakis7, John S. Sampalis7, May Shawi8, Francois Nantel9, Susan M. Otawa10 and Allen J. Lehman10, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 3University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 5Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 6Rheumatology, Windsor, ON, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, 9Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose:   Efficacy and safety of anti-TNF in rheumatoid arthritis (RA) management has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
  • Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials

    Ronald F. van Vollenhoven1, Andrea Rubbert-Roth2, Anthony Sebba3, Benjamin Porter-Brown4, Lucy Rowell5, Pavel Napalkov6 and Devi Smart5, 1Karolinska Institute, Stockholm, Sweden, 2Med Clinic I, University of Cologne, koln, Germany, 3University of South Florida, Tampa, FL, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Roche, Welwyn Garden City, United Kingdom, 6Epidemiology, Genentech, South San Francisco, CA

    Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
  • Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting

    Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis

    Charles Inderjeeth1, Andrew Redfern1, Michael Huang2, Yun Hardiman2, Theresa Grant2, Lawrence C. Fritz2, David Fuller3, David Haughey4 and Mark C. Totoritis2, 1Linear Clinical Research Ltd, Perth, Australia, 2Santarus, Inc., San Diego, CA, 3INC Research, Inc., New South Wales, Australia, 4ICON Development Solutions, Whitesboro, NY

    Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…
  • Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs

    G. R. Burmester1, C Charles-Schoeman2, J. D. Isaacs3, T. Hendrikx4, K. Kwok5, S. H. Zwillich6 and R. Riese6, 1Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, 2University of California, Los Angeles, CA, 3Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Pfizer BV, Capelle aan den IJssel, Netherlands, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
  • Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection

    Janet van Adelsberg1, Steven P. Weinstein2, Neil Graham3, Tanya Momtahen4, Chunpeng Fan5 and Stefano Fiore6, 1Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 2Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 3Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Program Direction, Sanofi, Bridgewater, NJ, 5Biostatistics, Sanofi, Bridgewater, NJ, 6Clinical Science, Sanofi, Bridgewater, NJ

    Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
  • Abstract Number: 1454 • 2013 ACR/ARHP Annual Meeting

    The Effects Of The Spleen Tyrosine Kinase Inhibitor Fostamatinib On Ambulatory Blood Pressure In Patients With Active Rheumatoid Arthritis – Results Of The Oskira Ambulatory Blood Pressure Monitoring Trial

    G Kitas1, G Abreu2, K Jedrychowicz-Rosiak3, J Miller4, R Nakov2, S Panfilov2, J Vencovsky5, M Wang6, M Weinblatt7 and WB White8, 1The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, 2AstraZeneca, Molndal, Molndal, Sweden, 3MCBK SC, Grodzisk Mazowiecki, Poland, 4S.W. Florida Clinical Research Center, Florida, FL, 5Institute of Rheumatology, Prague, Czech Republic, 6AstraZeneca, Alderley Park, Macclesfield, United Kingdom, 7Brigham and Women's Hospital, Boston, MA, 8Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT

    Background/Purpose: Fostamatinib (Fosta) is a spleen tyrosine kinase (SYK) inhibitor in clinical trials in patients (pts) with rheumatoid arthritis (RA). Previous clinical studies showed blood…
  • Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting

    Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy

    A. Dikranian1, K. Soma2, R. Riese2, D. Gruben2 and T. V. Jones3, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology